A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Trees's Debt-to-EBITDA or its related term are showing as below:
CANN's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.66 * Ranked among companies with meaningful Debt-to-EBITDA only.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Trees Debt-to-EBITDA Related Terms
Trees Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Trees's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CANN vs RAPH, LIFD, SHPH: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Trees's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Trees Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Trees's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Trees's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Sep. 2024) EBITDA data.
Trees (CANN) has a Debt-to-EBITDA of 544.44 as of Sep. 2024. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Trees.
Is Trees' Debt-to-EBITDA too high?
Trees' current Debt-to-EBITDA is 544.44. The Drug Manufacturers industry median Debt-to-EBITDA is 1.66. Trees' value of 544.44 is 32697.6% above this industry median. Overall, Trees has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Trees' Debt-to-EBITDA compare to RAPH and LIFD?
Trees' Debt-to-EBITDA of 544.44 can be compared against companies in the Drug Manufacturers industry. The industry median Debt-to-EBITDA is 1.66. Trees' value of 544.44 is 32697.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.66, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Trees's current Debt-to-EBITDA of 544.44 is 32697.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Trees. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Trees's current Debt-to-EBITDA is 544.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trees stock overvalued right now?
Trees (CANN) has a current Debt-to-EBITDA of 544.44. The current Debt-to-EBITDA is 544.44 and 32697.6% above the Drug Manufacturers industry median of 1.66. Trees' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Trees (CANN), the current Debt-to-EBITDA is 544.44 as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Trees Corp is a vertically integrated cannabis company and multi-state operator in the United States. It has two segments Retail and Cultivation. It is pursuing a roll-up plan of licensed assets in mature markets while maintaining loyal, local customer bases. TREES owns and operates a light-deprivation greenhouse and a campus of indoor cultivation facilities in Boulder, dispensaries in Englewood, Longmont, and Berthoud, Colorado, and three dispensaries in Portland, Oregon.
12GF Score
Get the complete analysis for CANN
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CANN has been successfully added to your 
